Latest news with #Plus'
NZ Herald
12-05-2025
- Business
- NZ Herald
Air New Zealand plans ‘Elite Plus' frequent flyer tier, new exclusive lounge at Auckland Airport
The airline's lounges were 'a highly valued part of the travel experience for many of our customers, whether they're flying within New Zealand or internationally', Air New Zealand chief commercial officer Jeremy O'Brien told the Herald. 'We're always looking for ways to enhance that experience, including exploring the development of a new premium lounge at Auckland International Airport. 'As part of this, we're reviewing how the planned redevelopment at Auckland Airport could shape our lounge offerings in the future.' Elite Lounge Work will begin on constructing Air New Zealand 's new Elite lounge in the next six months, coinciding with a complete renovation of its current lounge at Auckland Airport, O'Brien told Executive Traveller. Rather than dividing space in the current lounge, which has become prone to over-crowding, the airline plans to take on more floorspace to accommodate the new premium lounge. 'We'll be able to give a full elite experience to customers,' O'Brien said. Unfettered access would only be available for Elite, 'Elite Plus' and Elite Priority One members, along with those flying Business Premier. Airpoints Gold and Star Alliance Gold members would still be able to access the main lounge as usual. 'One of the options will be a lounge area for Elite members and Business Class passengers,' O'Brien said. Construction dates remained tentative. Air New Zealand's two-tiered lounge plan is not a new concept. Qantas, which had a premium lounge at Auckland Airport before it closed in April for renovations, has provided passengers with tiered lounge options at many of its hubs. 'Elite Plus' frequent flier tier O'Brien told Executive Traveller that the long-rumoured 'Elite Plus' tier 'will be announced in the next six months', with the new lounge likely being revealed at the same time. '[Members will] have preferential access, priority around upgrades and cabin seating, those sorts of things.' While the new tier's name was confirmed frequent flyers would have to wait until the formal announcement to hear more, O'Brien said. Air New Zealand has eyed the expansion of its Airpoints programme since at least 2020, when Airpoints Elite members were asked what perks they would expect from an 'Elite Plus' tier in a select survey. At the time, the airline was considering benefits such as an upgrade request guarantee based on seat availability, free 'home airport' parking, and the chance for members to nominate a companion to fly with them free of charge. Air New Zealand's former loyalty boss, Kate O'Brien, said during the airline's 2024 Investor Day that Airpoints members had responded well to the airline's latest suggestions, especially that of an exclusive lounge for those at Elite level or above.
Hindustan Times
22-04-2025
- Hindustan Times
iPhone 17 Air will be super thin but Apple will not compromise on battery life
This year, Apple is expected to introduce a new ultra-slim iPhone model, the iPhone 17 Air. This model will likely replace the 'Plus' variants, bringing something new and unique to the iPhone series. While reports surrounding the iPhone 17 Air and its slimness may excite buyers, the smartphone will likely come with several trade-offs. Some of the compromises could include a single rear camera, no physical SIM slot, a single speaker, and others. However, one of the most talked-about worries for the iPhone 17 Air is the battery life, and whether Apple will compromise on battery size to maintain the desired slimness. Well, several analysts and industry experts, such as Bloomberg's Mark Gurman and Ming-Chi Kuo, have shown little enthusiasm surrounding iPhone 17 Air battery life. Therefore, while the iPhone 17 Air may compromise on a few features, battery life may not be a major concern due to these two crucial factors. Also read: iPhone 17 Air could launch in September 2025 — Key details revealed The iPhone 17 Air is expected to have a 5.5mm thickness, making it the slimmest iPhone ever. However, with this amount of slimness, the smartphone could come with several compromises. However, reports suggest that the iPhone 17 Air will not trade-off the battery life for slimness as Apple is expected to bring two major changes to the hardware. According to Mark Gurman, the iPhone 17 Air will likely feature a 'redesigned display and silicon components' that claim to enhance the smartphone's efficiency, resulting in less power consumption. On the other hand, it will likely come equipped with high-density battery cells that will provide more battery capacity to the smartphone, despite being slimmer or compact in size. Although there are very limited details surrounding the new battery cells. Therefore, reports suggest that these two additions could ensure lasting performance without any major compromise on the battery life. Also read: iPhone 17 Air vs iPhone 17 Pro Max: Leaked image reveals notable difference in thickness Another factor for boosting battery life could be the addition of Apple's new C1 chip, which currently powers the iPhone 16e model. This new 5G modem has proven to consume less battery, resulting in increased battery life for the affordable iPhone model. Over the years, Apple has drastically improved battery life due to a thicker battery life, but considering the thinner iPads, we can expect the company to work on new redesigned elements for the iPhone 17 Air. As we get closer to the spring launch, we expect to hear more about the smartphone's design and how Apple plans to manage the battery life of the smartphone. Mobile finder: iPhone 17 LATEST price, specs and all details
Yahoo
10-03-2025
- Business
- Yahoo
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
Rhenium (186Re) Obisbemeda demonstrates safety, response, and potential efficacy for glioblastoma (GBM) patients Patients receiving >100 Gy of Rhenium (186Re) Obisbemeda achieved a median overall survival of 17 months, more than double the 8-month median overall survival with standard of care HOUSTON, March 07, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ('Plus' or the 'Company'), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the publication of results in a peer-reviewed manuscript titled, "Treatment of Recurrent Glioma by Rhenium (186Re) Obisbemeda (186RNL): a Phase 1 clinical trial" in the peer-reviewed medical journal Nature Communications. 'Peer-reviewed publication of our Phase 1 glioma data in a prestigious, high-impact factor journal is substantial validation for this important clinical program,' said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. 'Based largely on this data, our ReSPECT-GBM Phase 2 trial is currently enrolling patients at leading medical centers, bringing us closer to delivering a much-needed treatment option for this devastating disease.' Key highlights from the publication: Twenty-one patients were treated with doses up to 22.3 mCi of Rhenium (186Re) Obisbemeda No dose-limiting toxicity was observed, and most adverse events were unrelated to the study treatment Median overall survival (OS) was 11 months, surpassing the standard of care for recurrent glioblastoma, which is approximately 8 months Median OS was strongly correlated with radiation absorbed dose to the tumor and the percentage of tumor treated Patients receiving >100 Gy (n=12) had a median OS of 17 months, compared to 6 months for those receiving <100 Gy (n=9) (p=0.001) Absorbed radiation doses to the tumor were as high as 739.5 Gy and were delivered without significant toxicity, exceeding levels achievable with external beam radiation therapy The full manuscript can be accessed here. The ReSPECT-GBM trial is actively enrolling patients; additional information about the ReSPECT-GBM trial can be found here. About Recurrent Glioblastoma (GBM) GBM affects approximately 15,000 patients annually in the U.S. and is the most common and lethal form of brain cancer. The average life expectancy with GBM is less than 24 months, with a one-year survival rate of 40% and a five-year survival rate of around 5%. There is no clear standard of care for recurrent GBM and the few currently approved treatments provide only marginal survival benefit and are associated with significant side effects, which limit dosing and prolonged use. Approximately 90% of patients experience GBM tumor recurrence at or near the original tumor location, yet there are no FDA-approved treatments in the recurrent or progressive setting that can significantly extend a patient's life. About Rhenium (186Re) Obisbemeda Rhenium (186Re) Obisbemeda is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. Rhenium (186Re) Obisbemeda has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. Rhenium (186Re) Obisbemeda is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT). About Convection-Enhanced Delivery Convection Enhanced Delivery (CED) is a therapeutic strategy that was developed to facilitate targeted delivery of pharmaceuticals to the brain. The CED procedure involves a minimally invasive surgical exposure of the brain, followed by placement of small diameter catheters directly into the brain tumor. About Plus TherapeuticsPlus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit Cautionary Statement Regarding Forward-Looking StatementsThis presentation contains statements that may be deemed 'forward-looking statements' within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as 'potential,' 'anticipating,' 'planning' and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of Rhenium (186Re) Obisbemeda including the ability of Rhenium (186Re) Obisbemeda to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company's future performance including the next steps in developing the Company's current assets; the Company's clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM, ReSPECT-LM and ReSPECT-PBC, clinical trials; possible negative effects of Rhenium (186Re) Obisbemeda; the continued evaluation of Rhenium (186Re) Obisbemeda including through evaluations in additional patient cohorts; the intended functions of the Company's platform and expected benefits from such functions; and the development, utility and potential of the CNSide leptomeningeal metastases diagnostic test. The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company's product candidates and therapies, the results of the Company's research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company's liquidity and capital resources and its ability to raise additional cash, the outcome of the Company's partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms, and material security breach or cybersecurity attack affecting the Company's operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics' business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics' annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC's website at Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so. Investor ContactCharles Y. Huang, MBADirector of Capital Markets and Investor RelationsOffice: (202)-209-5751 | Direct (301)-728-7222chuang@ in to access your portfolio
